HIV treatment for children to be produced for under one dollar a day

Geneva, Switzerland – 29 November 2019
Unitaid and DNDi celebrate partnership with Cipla on World AIDS Day
The Indian pharmaceutical company Cipla has announced their commitment to price the ground-breaking new product Quadrimune, a “4‑in‑1” treatment for young children with HIV, at below a dollar a day. Quadrimune is currently under review by the US Food and Drug Administration (FDA) for use in children between 3 and 25 kg bodyweight.

Un traitement anti-VIH pédiatrique à moins d’un dollar par jour

Genève, Suisse – le 29 novembre 2019
À l’occasion de la Journée mondiale de lutte contre le sida, Unitaid et DNDi célèbrent leur partenariat avec Cipla
Cipla, le groupe pharmaceutique indien, s’est engagé à ce que le prix de son nouveau médicament révolutionnaire, le Quadrimune, ne dépasse pas un dollar par jour. Ce traitement « 4 en 1 » destiné aux jeunes enfants atteints du VIH est actuellement examiné par la FDA (US Food and Drug Administration) pour une utilisation chez l’enfant pesant de 3 à 25 kg.

ICID 2020

20-23 February 2020
Kuala Lumpur, Malaysia

  • DNDi is a collaborating organization

Not-for-profit research and development can address deadly market failure for neglected patients, paper shows

Berlin, Germany – 30 October 2019
15 years of an ‘experiment in innovation’ to discover and develop affordable new treatments in the public interest
In its first 15 years, DNDi has proven that not-for-profit R&D can deliver effective and affordable new treatments to help fill the drug development pipeline for neglected diseases, an area that was suffering from a deadly lack of attention when the organization was created in 2003, according to a new report released today at the two-day DNDi & Founders’ Symposium in Berlin, Germany.

PAHO secures significant price reductions for hepatitis C medicines

The Pan-American Health Organization (PAHO) has succeeded in reducing the price of expensive medicines that can cure people living with hepatitis C (HCV), according to an announcement made at its 57th Directing Council meeting. This significant a move could enable national programmes to scale up diagnosis and treatment and eliminate HCV as a public health problem.

Lack of awareness of Chagas disease in the US leading to unnecessary deaths in vulnerable immigrant communities

New York/Los Angeles – 26 September 2019
New DNDi/CECD/MSF paper published in PLOS Neglected Tropical Diseases on the “silent killer” Chagas disease
Fear, stigma, gaps in the health system, and lack of awareness in the medical community are among the barriers keeping the most vulnerable from accessing essential care for Chagas disease, a leading cause of heart disease in the Americas, according to a paper published today by the not-for-profit drug development organization DNDi, the Center of Excellence for Chagas Disease, and the international medical humanitarian organization MSF.

La falta de concientización sobre la enfermedad de Chagas en los EEUU está causando muertes prevenibles en comunidades de inmigrantes vulnerables

Nueva York/Los Ángeles – 26 September 2019
Nuevo artículo de DNDi/CECD/MSF publicado en PLOS Neglected Tropical Diseases sobre la enfermedad de Chagas, “el asesino silencioso”.
El miedo, las brechas en el sistema de salud y la falta de concientización son algunas de las barreras que impiden el acceso de los más vulnerables al tratamiento de la enfermedad de Chagas, una de las principales causas de problemas cardíacos en las Américas, según un artículo publicado por la organización sin fines de lucro de desarrollo de medicamentos iniciativa Medicamentos para Enfermedades Olvidadas (DNDi, por su acrónimo en inglés), el Center of Excellence for Chagas Disease (CECD) del centro médico Olive View de la UCLA y la organización humanitaria médica internacional Médicos Sin Fronteras (MSF).